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Abstract
Background: Pain and fatigue are persistent problems in people with rheumatoid arthritis. Central sensitisation (CS)
may contribute to pain and fatigue, even when treatment has controlled inflammatory disease. This study
aims to validate a self-report 8-item questionnaire, the Central Aspects of Pain in Rheumatoid Arthritis (CAP-
RA) questionnaire, developed to measure central pain mechanisms in RA, and to predict patient outcomes
and response to treatment. A secondary objective is to explore mechanisms linking CS, pain and fatigue in
people with RA.
Methods/design: This is a prospective observational cohort study recruiting 250 adults with active RA in
secondary care. The CAP-RA questionnaire, demographic data, medical history, and patient reported outcome
measures (PROMs) of traits associated with central sensitization will be collected using validated
questionnaires. Quantitative sensory testing modalities of pressure pain detection thresholds, temporal
summation and conditioned pain modulation will be indices of central sensitization, and blood markers,
swollen joints and ultrasound scans will be indices of inflammation. Primary data collection will be at baseline
and 12 weeks. The test-retest reliability of CAP-RA questionnaire will be determined 1 week after the baseline
visit. Pain and fatigue data will be collected weekly via text messages for 12 weeks. CAP-RA psychometric
properties, and predictive validity for outcomes at 3 months will be evaluated.
Discussion: This study will validate a simple self-report questionnaire against psychophysical indices of central
sensitization and patient reported outcome measures of traits associated with CS in a population of
individuals with active RA. The application of this instrument in the clinical environment could provide a
mechanism-based stratification tool to facilitate the provision of targeted therapy to individuals with pain and
fatigue in RA, alongside treatments that target joint inflammation.
Trial registration: Clinicaltrials.gov NCT04515589. Date of registration 17 August 2020.
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Background
Rheumatoid Arthritis is a (RA) chronic autoimmune in-
flammatory disease affecting hands, feet and other joints.
RA typically presents with pain, joint stiffness, and fa-
tigue. It may be associated with extra-articular inflam-
mation affecting, for example, lungs or eyes [1]. RA runs
a relapsing and remitting course through the lifetime of
an individual. There is currently no cure, but inflamma-
tory disease can usually be controlled using conventional
or biologic Disease Modifying Anti-Rheumatic Drugs
(DMARDs). New treatment regimens incorporating early
intensive DMARD treatment have contributed to im-
proving quality of life of people with RA.
DMARDs produce and sustain remission of inflam-
matory disease for many people, but, even then, per-
sistent pain and fatigue can remain major problems.
On average, pain incompletely improves after DMAR
D therapy, with 80% of people who considered their
disease to be well controlled continuing to report
pain [2]. The prevalence of clinically important pain
among people with sustained RA disease remission
longer than 1 year is about 12% [3]. About 40% of pa-
tients with well controlled inflammatory disease re-
ported persistent fatigue [4, 5].
Pain and fatigue in RA arise from complex and over-
lapping mechanisms involving inflammation, structural
joint changes, central and peripheral pain processing, as
well as psychosocial factors, health beliefs and illness
perceptions [6, 7]. In RA, pain results from interactions
between multiple mechanisms in the peripheral and cen-
tral nervous systems. Individuals with RA pain describe
it as aching or gnawing suggesting a nociceptive pain,
and some describe it as ‘shooting’ or ‘burning’, which is
characteristic of neuropathic pain [6]. RA pain may have
nociplastic features, described as widespread, and with-
out evidence of commensurate tissue or nerve damage
[8]. Nociplastic pain may be due to central sensitization
[9, 10]. Central sensitization is a phenomenon charac-
terised by increased responsiveness of nociceptive neu-
rons in the central nervous system to their normal or
subthreshold afferent input. CS may be associated with
fatigue independent of pain [11], although people with
Chronic Fatigue Syndrome often experience widespread
pain [12, 13], and people with fibromyalgia experience
chronic fatigue.
Central mechanisms are thought to drive pain and fa-
tigue in the presence of well controlled inflammatory dis-
ease. The disease activity score in 28 joints (DAS28) is a
specific quantitative clinical index to assess and monitor
disease activity in RA [14] and CS may increase patient-
reported components of DAS28 - tender joint count (TJC)
and visual analogue scores (VAS), worsening the DAS28
score in the absence of concordant inflammation [15]. In
these circumstances misclassification of active disease
could result in increased use of DMARDs, exposing
people to the risk of adverse events without real prospect
of benefit [16]. Too narrow a focus on suppressing inflam-
mation can displace the introduction of adjunctive treat-
ments that might reduce central sensitisation and improve
long-term pain and fatigue in RA.
Current RA treatment guidelines adopt a ‘one size fits
all’ approach to pain management, mainly targeted at
nociceptive pain [17]. However, different pain mecha-
nisms represent different targets for pain management
and their measurement might permit stratified or
precision treatment delivery to alleviate pain in people
with RA. Furthermore, available evidence describes a
heterogenous RA population with varying prognosis and
treatment responses in terms of disease activity, pain,
fatigue, functional limitations, and psychological distress
[18–22]. Distinct pain mechanisms as well as
heterogenous symptom response presents an opportun-
ity for targeted interventions for symptom control e.g.
people with persistent pain due to resistant joint inflam-
mation might benefit from a change in DMARD
strategy, whereas those with pain driven by central
mechanisms might better benefit from treatments that
target the central nervous system.
Several research studies have demonstrated an associ-
ation between central pain mechanisms and persistent
and severe pain in musculoskeletal conditions [23–26] A
stratification tool which identifies people with central
sensitisation could improve the treatment of RA pain.
Central pain mechanisms can be assessed using a variety
of methods, including quantitative sensory testing (QST)
[27–29] and self-report questionnaires [23, 30].QST in-
cludes several modalities that assess different aspects of
central pain processing [27]. Although QST shows
promise as a stratification tool, its application in clinical
settings is limited by logistic issues such as requiring
face to face contact with a trained practitioner and
test duration [28, 31]. Questionnaires permit econom-
ical assessment with relative ease and are suitable for
use with large populations and in busy clinical set-
tings. Questionnaires that can assess central pain
mechanisms should, therefore, be more amenable
than QST for standard applications in clinics and in
research.
A single page 8 item questionnaire, Central Aspects of
Pain in the knee (CAP-knee) was designed and validated
as a measurement and classification tool for central pain
augmentation in people with knee pain. This self-report
tool measures 8 characteristics strongly associated with
central pain mechanisms and predicts 1-year pain out-
comes in people with knee pain [23]. The Central As-
pects of Pain in RA (CAP-RA) is a minor adaptation of
the CAP-knee questionnaire for use in a RA population.
This study aims to further develop and validate the new
Ifesemen et al. BMC Rheumatology            (2021) 5:23 Page 2 of 10
self-report 8 item CAP-RA questionnaire for measuring
central pain mechanisms in RA.
Objectives
The primary objective is to:
1. to optimise and establish the psychometric
properties of CAP-RA and
Secondary objectives are to:
1. measure the ability of CAP-RA to identify people
with pain that is augmented by central mechanisms,
are destined to have poor pain outcomes despite
modern therapy directed at joint inflammation.
2. Investigate factors associated with worse RA pain or
fatigue at baseline and 3 months follow up
3. Compare the performance of CAP-RA to other pre-
dictors of pain outcomes
4. Derive CAP-RA scoring recommendations for
stratification in clinical trials and in clinical practice
5. Examine associations between pain, central
sensitization and fatigue in RA.
6. Examine the short-term course of pain and fatigue
in RA
Methods/design
Study design and setting
CAP-RA is an observational prospective study based in
secondary care. Adults with RA who meet the study in-
clusion criteria will be recruited through secondary care
rheumatology services (Sherwood Forest Hospitals NHS
Foundation Trust; SFH). Participants will undergo clin-
ical assessments, blood tests, ultrasound scans and
complete the study questionnaire booklet at baseline,
and 12 weeks later. A consecutive sample of participants
will in addition complete the CAP-RA questionnaire 1
week after the baseline visit.
Ethical considerations and study sponsor
The study submitted to the national integrated re-
search application system (IRAS) and was reviewed
and approved by the North of Scotland Research Eth-
ics Committee (1) (reference no: 20/NS/0036) and
will be performed in accordance with the UK policy
framework for Health and Social Care Research, 2018,
principles of good clinical practice and Helsinki Dec-
laration. A SPIRIT 2013 statement checklist [32] is
included in supplement 1. The CAP-RA study spon-
sor is the University of Nottingham (which supervises
data management procedures, ethics amendment pro-
cesses/dissemination, and study stopping guidelines)
and the current protocol is version 1.2,18/08/2020.
Samples of all study related documents including
consent forms and participant communication are
also included in supplement 2 and 3.
Informed consent will be sought and confirmed
through a signed consent form at the start of the first
study visit before commencing study procedures. Par-
ticipants would be explicitly informed that partaking
in the study would not affect the participant’s entitle-
ments, treatment, or care during the study or in the
future; and would not require or preclude participa-
tion in other research projects. Details about how to
report study concerns or medical issues are also
provided.
Public and patient involvement and engagement
People with RA and members of the public were in-
volved in the conceptualization and design of the study.
The original CAP-knee questionnaire was developed in
conjunction with patients and members of the general
public. The minor wording adjustments to the CAP-
knee questionnaire to suit a RA population were under-
taken jointly by researchers (OSI, KAA, DMcW) and
patients through face to face meetings and by email. In
addition, the CAP-RA study steering committee charged
with overall management of the study comprises re-
searchers and people with RA. The steering committee
is charged with monitoring all aspects of study and en-
suring that study conduct adheres to the study protocol
and timescales.
Participants will be updated on research progress
through newsletters. Research findings will be dissemi-
nated though multiple routes, such as spoken presenta-
tions, conference abstracts, online and in academic
publications.
Participants
Inclusion criteria: All of the following
 Adults aged 18 years and above
 Satisfy the European League Against Rheumatism
(EULAR) criteria for RA [33]
 Have active RA, as defined as DAS28 ≥ 3.2 at the
baseline visit
 Pain levels > 3 on a 0 to 10 numerical rating scale
where 0 = no pain and 10 = worst imaginable pain.
 Ability to give informed consent
Exclusion criteria: Any of the following -
 Unable to give informed consent
 Insufficient understanding of spoken or written
English to comply with the requirements of the
study protocol.
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 Unable or unlikely to complete the proposed 12-
week study follow up (e.g moving house, terminal
diagnosis, current or planned pregnancy).
 Active co-morbidity (e.g uncontrolled diabetes melli-
tus, cancer, infection) requiring changes in medical
treatment at baseline.
 Major active psychiatric condition (e.g major
depression)
 Inability to meet the requirements of clinical
assessments
Recruitment
Participants will be recruited from secondary care. Out-
patient records will be screened by a member of the
clinical care team, and eligible participants will be con-
tacted by letter and invited to join the study. The study
will be publicised in posters placed in public areas within
clinics/hospitals. Additionally, members of the research
team will recruit participants via face:face discussions in
Rheumatology outpatient clinics in accordance with
local policies.
Study regimen
The baseline and 12-week study visits will be held in a
private clinic room. At the baseline visit, the partici-
pant’s eligibility will be verified, and informed consent
will be obtained. The baseline and 12-week study assess-
ments will have identical data collection protocols. A
time window of 12–16 weeks will be acceptable for the
follow up assessment. At 1 week after baseline assess-
ment, a subset of 80 people will be invited to complete
and return a postal questionnaire consisting of only the
8-item CAP-RA questionnaire to examine test-retest re-
liability. For the study duration, participants may opt-in
to receive and respond to SMS text messages asking
about weekly pain and fatigue levels. The study regimen
is described in Fig. 1.
Fig. 1 Schematic diagram of CAP-RA study regimen
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Data collection
Questionnaire
The study questionnaire booklet was developed using
validated instruments as well as the newly designed
CAP-RA questionnaire.
RA pain will be measured using 0–10 numerical rating
scale and fatigue [34], using the Bristol RA Fatigue Scale
(BRAFS) multidimensional questionnaire [35].
Traits associated with central pain mechanisms will be
assessed using the CAP-RA questionnaire and the Cen-
tral Sensitization Inventory short form-9(CSI-9) [36, 37].
Information on neuropathic-like pain will be collected
by a modified painDETECT questionnaire [38]. The
waveform and pain intensity questions were removed as
these are not included in the neuropathic pain score,
and questions were reworded as statements for easy
readability. Additionally, the questionnaire will utilise,
the pain catastrophising scale (PSC) [39], and the Bristol
RA Fatigue Scale (BRAFS) multi-dimensional question-
naire [35]. Depression and anxiety will be measured
using the Hospital Anxiety and Depression Scale
(HADS) [40]; functional ability,; and sleep, by the Athens
Insomnia Scale (ASC) [41]. Cognitive function will be
measured using the Cognitive Failures Questionnaire
(CFQ) [42].
The questionnaire will also address conditions, treat-
ments and outcomes that are associated with central
pain mechanisms and fatigue. The presence of fibro-
myalgia will be classified using pain distribution from a
self-completed whole-body manikin, to derive the Wide-
spread Pain Index (WPI), and Symptom Severity Score
(SSS) [43, 44]. Disability and physical activity will be
assessed with the Health Assessment Questionnaire
(HAQ) [45] and the short International Physical Activity
Questionnaires (IPAQ) [46] respectively. Demographic
characteristics will be recorded, and comorbidities re-
quired to calculate the Rheumatic Disease Co-Morbidity
Index (RDCI) will be assessed [47]. A detailed medica-
tion history will be collected, including common medica-
tions used to manage RA, common pain medications e.g.
nonsteroidal anti-inflammatory drugs (NSAIDs),
paracetamol.
Clinical assessment
During the study visits, participants will undergo the fol-
lowing data collection procedures
i. Study questionnaire will be administered to all
participants. The questionnaire booklet will be self-
completed by the participant.
ii. A 1 min cognition test will be performed where the
participant names as many animals as possible from
memory [48].
iii. DAS28: Tender and Swollen joint count assessment:
28 joints, the 10 metacarpophalangeal (MCP), 10
proximal interphalangeal (PIP), 2 wrist, 2 elbow, 2
shoulder and 2 knee joints will be examined for
tenderness and swelling [49]. Patient Global
Assessment (PGA) of disease activity will be
assessed using a visual analogue scale. DAS28-ESR
will be estimated using the following formula
Equation 1: DAS28 ESR Calculation [50]
DAS28 ¼ 0:56 ffiffiffiffiffiffiffiffiffiffiT JCp þ 0:28 ffiffiffiffiffiffiffiffiffiS JCp þ 0:70
 lnESRþ 0:014 PGA
iv. Quantitative sensory testing will be conducted using
Pressure Pain detection Threshold (PPT), Temporal
Summation (TS) and Conditioned Pain Modulation
(CPM) tests. PPT involves the assessment of
mechanical pressure pain thresholds using a
handheld computerised pressure algometer (Medoc
Algomed – Computerised Pressure Algometer).
The algometer consists of a rod with a 1 cm
diameter circular end and is applied perpendicular
to the test site. Pressure is applied through the
algometer at a standardised rate until the
participant presses a button indicating a change in
sensation from pressure to pain, when the
algometer is immediately removed and the pressure
reading recorded. Three measurements will be
collected at each site, with a short rest between
measurements. Participants will be familiarized with
the procedure by performing it on a different test
site before commencing the test. PPT will be
conducted on three anatomical sites, the body of
the brachioradialis muscle of the non-dominant
forearm, the medial tibiofemoral joint line, and the
body of the tibialis anterior muscle of the dominant
side [51].
Temporal summation (TS) tests the nervous
systems responsiveness to repeated noxious stimuli.
It will be conducted using a supra-threshold pin-
prick stimulator (256mN pinprick), which is applied
repeatedly to a single point on the skin over the pa-
tella ligament, in a single test and on a train of 10
repetitions, with intervals of 1 s in between repeti-
tions. The participants will be asked to indicate the
intensity of pain on a 0–100 visual analogue scale
(where 0 represents no pain and 100, the most
intense pain imaginable) for the single test, and
the average pain intensity for the series. The dif-
ference between the 2 self-reports will be used to
measure TS.
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Conditioned Pain Modulation (CPM) is conducted
using the PPT test (test stimulus). The test stimulus
is applied to the body of the tibialis anterior muscle
contralateral to the participant’s dominant hand
before and after induction of a painful stimulus at a
remote anatomical site. This conditioning stimulus
is achieved by applying a blood pressure cuff to the
dominant arm and inflating until the radial pulse
can no longer be palpated. The participant may be
asked to perform hand exercises (squeezing a stress
ball) to induce exercise induced ischaemic pain or
discomfort. As soon as the pain or discomfort in
the forearm is rated as 4/10 by the participant, they
stop squeezing the ball and the second PPT test is
performed. Only one CPM test will be performed.
CPM is calculated as [52]:
Equation 2: CPM Calculation
CPM ¼ PPTpost−PPTpre
xxii.Joint inflammation (synovitis and tenosynovitis) will
be assessed by ultrasound scans of the hands and
feet in both grayscale (GS) and power Doppler (PD)
modes. Examinations will be conducted according
to the EULAR guidelines for MSK ultrasound scans
in rheumatology [53]. Joint inflammation will be
assessed using the OMERACT US group scoring
criteria [54, 55].
xxiii.Blood samples will be obtained for inflammatory
biomarker (Erythrocyte Sedimentation Rate (ESR),
and C-Reactive Protein (CRP) assays, and samples
may be stored for additional biomarker analyses.
Additional data collection
The CAP-RA questionnaire will, in addition, be mailed
for completion by 80 consecutive participants 1 week
after the baseline visit, to assess test-retest reliability.
The course of fatigue and pain will be assessed by
sending participants weekly SMS text messages at ap-
proximately the same time each week, with the question
“On a scale of 0 – 10, with 0 indicating no pain, and 10
indicating the worst imaginable pain, how would you
rate your pain during the past week? Please respond to
this message with a number. Thank you”. The equivalent
question wording will be used to ask about weekly
fatigue.
Statistical analysis
The primary objective of the study is to determine the
psychometric properties of the new CAP-RA question-
naire. The psychometric properties examined will
include structural validity, construct hypothesis testing,
internal consistency, reliability, measurement error and
criterion validity, in accordance with Consensus-based
Standards for the selection of health Measurement In-
struments (COSMIN) guidelines [56–58].
Structural validity measures the degree to which the
scores in a patient reported outcome measure reflect the
dimensionality of the construct to be measured. Struc-
tural validity will be assessed using confirmatory factor
analysis (CFA) and Rasch modelling. A suitable polyto-
mous Rasch model will be selected [56]. The unidimen-
sional and local independence assumptions will be
examined and model fit parameters will be estimated
[59]. The construct validity of the CAP-RA question-
naire, a measure of the degree to which scores are con-
sistent with a hypothesis that is based on the assumption
that the PROM validly measures the intended construct,
will be investigated using confirmatory factor analysis.
Appropriate fit statistics will be calculated [60]. Internal
consistency, which is a measure of the degree of inter-
relatedness among items in the questionnaire will be es-
timated using Cronbach’s alpha, with a value greater
than 0.70 signifying acceptable internal consistency [61].
Test-retest reliability will be estimated using the Intra-
class Correlation Coefficient, with acceptable values
≥0.70 [62]. Measurement error will be estimated by the
Standard Error of Measurement (SEM), Smallest Detect-
able Change (SDC) and the Limits of Agreement (LoA).
Criterion validity will be a measure of the degree to
which the instrument is an adequate reflection of central
sensitisation.
The relationship between baseline CAP-RA scores and
pain outcomes will be measured using regression ana-
lysis, with 12-week pain as the outcome variable and
baseline characteristics as covariates.
Secondary objectives will be addressed using appropri-
ate regression analysis. For example, the association be-
tween fatigue and central sensitization will be examined
using linear or non-linear regression analysis, based on
the distribution of the data, and the course of fatigue will
be examined using linear or non-linear mixed effect
models as indicated. CAP-RA questionnaire thresholds
for delimiting high levels of central pain mechanisms
will be derived through receiver operating curves plotted
using dichotomised outcome measures, such as the dif-
ferent QST measurements [56, 63].
Analyses will be undertaken using appropriate statis-
tical software. P values less than or equal to 0.05 will be
considered statistically significant unless otherwise
stated.
Sample size considerations
The overall study sample size has been calculated to de-
termine the structural validity of the instrument using
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Rasch analysis. Our Rasch model assumes that item
calibrations are within ±½ logit from stable values,
with a 99% confidence interval. This gives an overall
sample size of between 108 and 243, best to poor tar-
geting [64]. We expect 200 participants will complete
the study, from a sample of 250 participants. This is
in keeping with COSMIN recommendations for Rasch
analysis [56–58].
For longitudinal analysis over 12 weeks, we predict
that n = 200 people will complete both study visits. The
power calculation for a linear multiple regression with
CAP-RA plus 5 baseline covariates (each assumed to
have a correlation coefficient of 0.15 with the 12-week
pain) yielded a sample size of n = 164 for α = 0.05 and
power = 0.95.
Seventy-seven participants are required for the reliabil-
ity study to estimate an ICC of 0.8, with 2 ratings, alpha
of 0.05, 80% power, and a lower limit ICC not less than
0.6. Sample size calculation was implemented in R using
“ICC.sample.size package” [65, 66].
Discussion
CAP-RA questionnaire is a brief questionnaire that
encompasses traits associated with central pain mech-
anisms in one tool. This is a prospective study pri-
marily aimed at validating CAP-RA to measure and
ultimately stratify central pain mechanisms in people
with RA. The study is based on the premise that per-
sistent pain in RA, in some people is caused by cen-
tral mechanisms and that targeted adjuvant treatment
provided to this specific population would greatly im-
prove health outcomes in these individuals. If trans-
lated into the clinic, CAP-RA could help to assign
people with RA to their optimal treatment in a more
efficient manner.
The CAP-RA questionnaire will undergo rigorous
psychometric testing to establish it as a validated tool
to measure central pain mechanisms in individuals
with RA., Pain catastrophising, depression, anxiety,
neuropathic pain, pain distribution, sleep disturbance,
fatigue, and depression have been found to represent
a single ‘central mechanisms of pain’ trait in a popu-
lation with knee osteoarthritis [28]. This current study
will establish if these traits also characterise central
pain mechanisms are in another musculoskeletal dis-
order and might therefore have general validity across
a range of conditions. This study is also designed to
discover if other measures of central mechanisms are
able to predict future pain or fatigue, and hence to
validate our underlying mechanistic hypothesis. Previ-
ously validated instruments, such as the CSI-9, Pain-
DETECT and QST will be tested as predictors of
pain or fatigue in a similar way to CAP-RA. As in-
flammation, specifically synovitis, is a known cause of
RA pain, we will directly measure this with US to en-
sure that it is documented with sufficient detail and
that its contribution to pain and pain prognosis is in-
cluded within our analyses [67]. We predict that asso-
ciations between central mechanisms and RA pain are
moderated by inflammation. The scenario where
synovitis resolves or improves upon commencement
of a new DMARD, but pain persists, is of importance
to clinicians and patients alike.
The CAP-RA questionnaire will extend the reper-
toire of quick and self-administered tools specifically
designed to identify people with specific pain mecha-
nisms. The CSI was designed to identify and quantify
symptoms experienced by people with diagnoses such
as fibromyalgia that have been associated with central
sensitization. It has demonstrated good psychometric
properties in multiple patient populations, but does
not consider traits of neuropathic pain [36], which we
have previously found to be part of the Central
Mechanisms Trait in people with knee pain [68]. The
originator painDETECT questionnaire has also been
used to imply central pain augmentation in people
with RA [38], although this alone was inferior to the
central mechanisms trait in predicting PPT in people
with knee pain [23]. The Allodynia Symptom Check-
list is mostly used in people who suffer with head-
aches and has not been validated in a population with
MSK pain [69, 70]. Another recently developed 11-
item self-report questionnaire including items asses-
sing pain and somatic symptoms also has not been
validated in a RA population [71].
Limitations
Although a brief questionnaire may be acceptable to pa-
tients, and feasible in busy clinical practice or large epi-
demiological studies, its interpretation is inevitably
limited by its self-reported nature, and even validated
self-report instruments are prone to recall bias. Traits
assessed with the CAP-RA questionnaire are however
multifaceted and subjective precluding objective meas-
urement. We attempt to address this by testing CAP-RA
against QST, as a proxy for central pain mechanisms.
However, there is no gold standard for measuring CS
which is itself a multidimensional construct. We will use
a brief QST procedure which has been used in other re-
search studies to measure central pain mechanisms,
comprising both static (PPT) and dynamic (TS and
CPM) test modalities. Each QST modality might have
different measurement properties and indicate different
aspects of CS including spinal processing of nociceptive
signals and descending modulation. Only two timepoints
will be measured, and this study was not designed to
measure the ability of CAP-RA to predict persistent pain
in RA beyond 3months. This study will be conducted
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within a restricted geographical region (within the East
Midlands of the UK) with people who have active
rheumatoid arthritis measured by DAS28. Our findings
might have limited generalizability outside this popula-
tion. More bias may also occur with the weekly SMS text
messages, as subgroup of participants opting in to this
section of the study may not be representative. However,
usage of SMS texting has previously been shown to be
widely used in older populations with arthritis [72]. This
study is reported in line with SPIRIT guidelines [32] as
guidelines for cohort study protocols are not fully devel-
oped [73].
Conclusion
Pain and fatigue are persistent symptoms experienced
by people with RA, even in well controlled inflamma-
tory disease. Persistent pain and fatigue may be
caused by mechanisms within the central nervous sys-
tem linked to central sensitization. This study seeks
to validate a simple self-reported questionnaire to
identify central mechanisms in the clinical setting to
facilitate the identification of individuals who may
benefit from adjuvant treatments alongside those aim-
ing to reduce joint inflammation.
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